- Reference code :
- wf359
- Published date :
-
15 November 2000
- Expired date :
-
02 April 2028
AstraZeneca today announced that development of Zendra (clomethiazole) has been stopped following analysis of findings from the Class-I study which showed no efficacy benefits for patients suffering acute cases of stroke.
The Class-I study involved the treatment of 1,200 patients suffering major stroke over three years in the USA and Canada. Preliminary results of the study will be presented at the World Stroke Congress later this month.
Although Zendra was not a high priority project for AstraZeneca, the Class-I study represented important research into stroke, a difficult area of treatment with high unmet medical need.
Dr.Patrick Lyden, Co-ordinating Investigator of the Class-I trial and Director of the University of California/ Veterans' Affairs Stroke Center at San Diego, said: "While these results are disappointing, we continue to view stroke as a treatable disease and we will continue our search for effective treatments."
Further enquires to:
|
Steve Brown +44 (0)20 7304 5033 Lucy Williams +44 (0)20 7304 5034 |
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD - Stockholm
-
310.10 SEK
At 21-Nov-2009 04:32 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
